Ph(-)myeloproliferative neoplasms and the related risk factors
for stroke occurrence: Results from a registry of patients
treated with Anagrelide

J 2021

Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide

KOSTAL, Milan, Jiri SCHWARZ, Petra OVESNÁ, Miroslav PENKA, Petr DULICEK et. al.

Základní údaje

Originální název

Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide

Autoři

KOSTAL, Milan (203 Česká republika, garant), Jiri SCHWARZ (203 Česká republika), Petra OVESNÁ (203 Česká republika, domácí), Miroslav PENKA (203 Česká republika, domácí) a Petr DULICEK (203 Česká republika)

Vydání

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, DORDRECHT, SPRINGER, 2021, 0929-5305

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.221

Kód RIV

RIV/00216224:14110/21:00120658

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s11239-020-02175-8

UT WoS

000542529200001

Klíčová slova anglicky

Stroke; TIA; Myeloproliferation; Thrombosis; Risk factor; JAK2

Štítky

14110212, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 10. 2022 08:53, Mgr. Tereza Miškechová

Anotace

V originále

Arterial thrombosis is a common complication in patients with Ph(-)myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34-76) and of 53 years of age (ranging from 26-74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458-3.043, p = 0.006), age (OR 1.017/year, 1.005-1,029, p = 0.006), male gender (OR 1.419, 1.057-1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446-0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473-0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162-2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017-3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph-MPN patients.

Citovat

KOSTAL, Milan, Jiri SCHWARZ, Petra OVESNÁ, Miroslav PENKA a Petr DULICEK. Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide. JOURNAL OF THROMBOSIS AND THROMBOLYSIS. DORDRECHT: SPRINGER, 2021, roč. 51, č. 1, s. 112-119. ISSN 0929-5305. Dostupné z: https://dx.doi.org/10.1007/s11239-020-02175-8.

@article{1673164,
   author = {Kostal, Milan and Schwarz, Jiri and Ovesná, Petra and Penka, Miroslav and Dulicek, Petr},
   article_location = {DORDRECHT},
   article_number = {1},
   doi = {http://dx.doi.org/10.1007/s11239-020-02175-8},
   keywords = {Stroke; TIA; Myeloproliferation; Thrombosis; Risk factor; JAK2},
   language = {eng},
   issn = {0929-5305},
   journal = {JOURNAL OF THROMBOSIS AND THROMBOLYSIS},
   title = {Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide},
   url = {https://link.springer.com/article/10.1007%2Fs11239-020-02175-8},
   volume = {51},
   year = {2021}
}

TY  - JOUR
ID  - 1673164
AU  - Kostal, Milan - Schwarz, Jiri - Ovesná, Petra - Penka, Miroslav - Dulicek, Petr
PY  - 2021
TI  - Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide
JF  - JOURNAL OF THROMBOSIS AND THROMBOLYSIS
VL  - 51
IS  - 1
SP  - 112-119
EP  - 112-119
PB  - SPRINGER
SN  - 09295305
KW  - Stroke
KW  - TIA
KW  - Myeloproliferation
KW  - Thrombosis
KW  - Risk factor
KW  - JAK2
UR  - https://link.springer.com/article/10.1007%2Fs11239-020-02175-8
L2  - https://link.springer.com/article/10.1007%2Fs11239-020-02175-8
N2  - Arterial thrombosis is a common complication in patients with Ph(-)myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34-76) and of 53 years of age (ranging from 26-74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458-3.043, p = 0.006), age (OR 1.017/year, 1.005-1,029, p = 0.006), male gender (OR 1.419, 1.057-1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446-0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473-0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162-2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017-3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph-MPN patients.
ER  -

KOSTAL, Milan, Jiri SCHWARZ, Petra OVESNÁ, Miroslav PENKA a Petr DULICEK. Ph(-)myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide. \textit{JOURNAL OF THROMBOSIS AND THROMBOLYSIS}. DORDRECHT: SPRINGER, 2021, roč.~51, č.~1, s.~112-119. ISSN~0929-5305. Dostupné z: https://dx.doi.org/10.1007/s11239-020-02175-8.

Podrobný výpis o publikaci